

## PARTICIPANT INFORMATION SHEET AND CONSENT FORM- UK

Name of Study:	A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease
Short Title:	AL002 in participants with Early Alzheimer's disease
Study Number:	AL002-2
Study Sponsor	Alector, Inc. 131 Oyster Point Boulevard, Suite 600 South San Francisco, CA 94080, USA
Study Doctor (Investigator):	<a href="#">Dr Emer MacSweeney</a> <a href="#">Dr MacSweeney</a> Re: Cognition Health, Bristol Unit 240, Phase 200, Aztec West, Bristol, BS32 4SY 0117 462 3600 <a href="#">+44 (0)7540 802 222</a>
Ethics Committee	London – Brent Research Ethics Committee

### Invitation

You are being invited to participate in a clinical research study.

Joining the study is entirely up to you, before you decide we would like you to understand why the research is being done and what it would involve for you. One of our team will go through the information sheet with you, to help you decide whether you would like to take part and answer any questions you may have. Please feel free to talk to others about the study if you wish.

Do ask if anything is unclear. You are under no obligation to take part in this study – participation is entirely voluntary. If you agree to take part you will be asked to sign the Informed Consent Form at the end of this document. You will be given a signed and dated copy to keep.

The following information describes the study and your possible role as a participant. Please read this information carefully and do not hesitate to ask the study doctor any questions that you may have to ensure that you are able to make an informed decision on whether you would like to participate. If you agree to take part, you will be asked to sign and date this Informed Consent Form. You will be given a signed and dated copy to keep.

If you lose capacity during the study (e.g. if you're no longer able to make decisions about your medical care), you will also need a legally authorised representative. This is someone that you know (e.g. a partner, family member or close friend) who can give consent on your behalf if you are not able to. This may be your study partner, or someone else. This person must sign a separate form to give permission or consent for you to continue taking part in the study. You will be asked to confirm the identity of your legal representative before you start this study by completing the section at the end of this form. You do not have to continue in the study, even if your legal representative has signed the consent form.

### Study Partner Requirement

You will also need to have a spouse, family member, or friend participate in this study with you as your study partner. This person should have at least 10 hours of in-person contact with you each week and will be responsible for providing information about your memory and daily functioning to the study doctor or study staff during study visits. Your study partner must also agree to participate in this study by signing a separate Informed Consent Form.

### **What is the purpose of this clinical research study?**

A pharmaceutical company called Alector, Inc (to be known throughout this information sheet as "sponsor") developed an investigational drug called AL002 and is conducting this study. The sponsor is continuing to develop AL002 in collaboration with AbbVie Inc. and its affiliates (together known throughout this information sheets as "collaboration partner"). The purpose is to determine if AL002 is effective and safe in treating individuals who have Early Alzheimer's Disease (AD) when compared to placebo (a solution that is mostly salt water with no active AL002 drug). This means that we are interested in learning whether or not AL002 is helpful for treating AD. We are also doing this study to determine if AL002 is safe for you and other people with AD.

### **What is the drug that is being tested?**

This study will test an investigational drug called AL002 for the treatment of people who have Alzheimer's disease (AD). An investigational drug is a drug, or a form of a drug, that is not yet approved by regulatory authorities.

Alzheimer's disease is the most common type of dementia. It is a progressive brain disorder characterised by the build-up of proteins called "amyloid" in a person's brain. Alzheimer's disease usually affects a person's memory but can also affect behaviour, decision-making, and ability to perform everyday tasks. The process that results in disease often starts long before patients develop symptoms noticed by themselves or others.

Currently, there is no cure for Alzheimer's disease. There are drugs available that can help with some of the symptoms, however.

AL002 is a type of antibody. An antibody is a molecule that can bind to other molecules such as receptors. AL002 is designed to interact with a receptor called TREM2 to increase the microglia in the brain. Microglial cells are immune cells that are essential for maintaining brain health. We will evaluate the way the AL002 works in your brain by taking pictures with different types of imaging techniques and we will also ask you for some blood samples. We will be asking you and your study partner for information about your memory, other aspects of your thinking such as language, attention, and about your ability to problem-solve and organise. We will also ask some questions about your feelings. It is important for us to understand how you are doing in your everyday life.

We will also ask you if you are willing to do other assessments so that we can better understand the way AL002 works in your brain. These may include special types of brain scans that allow us to take pictures of the dysfunctional proteins, called beta amyloid and tau, that we think contribute to the development of AD. We may also ask you if you are willing to give us a sample of what is called cerebrospinal fluid (CSF). CSF is the protective fluid that surrounds your brain and spinal cord and it is also responsible for clearing waste from the brain. At this time, doing these types of brain scans and CSF collections are the only way we can directly measure what is happening with AL002 inside of your body. The procedures are described in more detail below, but we are also available to answer any questions you may have about them if you are interested.

### **Why have I been invited?**

You have been invited to participate in this research study because you have been diagnosed with Early Alzheimer's Disease.

### **Do I have to take part?**

No. It is up to you to decide. Your participation in this study is voluntary and you may refuse to participate or withdraw from the trial at any time without penalty or loss of benefits to which you are otherwise entitled. If you do decide to participate you will need to read this information sheet and sign a consent form to show you have agreed to take part.

### **Will any genetic tests be done?**

Genes are factors that you inherit from your parents that may influence your chances of developing a disease. You will be asked to provide a blood sample to find genetic markers

that are related to your Alzheimer's disease symptoms. The results of these tests will not be disclosed to you.

### How many people will be in this study?

The study will take place at approximately 90 study sites across North America, Australia, Europe and South America. If you agree to take part in this study, you will be one of approximately 265 participants. Each participant will be in one of two groups: Group 1 or Group 2.

Group 1 will contain approximately 40 participants, and Group 2 will contain approximately 225 participants. The first 40 participants enrolled in the study will be assigned to Group 1, and all participants enrolled after the first 40 participants will be assigned to Group 2. There is one additional visit and some additional procedures if you are in Group 1, that the study doctor will explain to you. You cannot choose which group you are in. At the time of consent you will be told which group you are expected to be in.

This is a placebo-controlled, double-blind, randomised study:

**Placebo-controlled** means that some participants will receive AL002, and some participants will receive placebo (a solution that is mostly saltwater with no active AL002 drug).

**Double-blind** means neither you nor your study doctor will know what study drug (AL002 or placebo) you are receiving.

**Randomised** means the study drug you receive will be chosen by chance, like flipping a coin.

- You will have 3 out of 4 chances to receive AL002 and 1 out of 4 chances to receive placebo.

### How long will I be in the study?

The length of time in the study will vary for each participant, dependent on when you are recruited to the study. Following the Screening Visit(s), if found suitable to participate, you will be treated for at least 48 weeks (up to a total of 13 doses) and up to 96 weeks (up to a total of 25 doses). Thereafter, you will attend 2 follow-up visits 4 and 8 weeks after your last dose of study drug.

Treatment will end when you reach 96 weeks of treatment or 48 weeks after the last participant is enrolled in the study, whichever occurs first.

If you decide to participate in this study, you will be asked to make a total of up to approximately 32 scheduled visits to the study site over about 28 months; each visit will take approximately 3 to 6 hours depending on the procedures completed at each visit. You may be asked to visit the study site for unscheduled extra visits at any time during the study if the study doctor decides that extra assessments are needed for your safety.

## What procedures are involved in this study?

The procedures, tests, and assessments that are involved in this study are described below.

The timing and frequency of the procedures and tests that will be performed will be discussed with you by the study doctor.

<b>Procedure or Test</b>	<b>Description</b>
Demographics	You will be asked some personal details about yourself, including your year of birth, age, gender, ethnicity, racial origin, education and if you are right or left-handed. This is called demographic data and will be used only for clinical research purposes.
Health, Social & Medication History	Your complete social, medical, surgical, and current disease history, including medication and any herbs or supplements or “health foods” taken, tobacco use (smoking, vaping, chewing), marital status, employment, alcohol consumption, cannabinoid and recreational drugs use will be obtained and reviewed by the study doctor or a qualified staff member.
Adverse Events and Medications You Are Taking	At each visit, the study doctor or qualified staff will review and document any health issues you may have recently experienced. Any medicine that you are currently taking or have taken since the previous visit will also be documented.
Physical Examination	A thorough physical examination will be performed by the study doctor or a qualified staff member. Your height will be recorded during the screening visit. Depending on the study visit, your doctor may conduct a short physical examination.
Neurological Examination	A thorough neurological examination will be performed by the study doctor or a qualified staff member.
Vital Signs & Weight	A measurement of your heart rate, breathing rate, blood pressure, and temperature (vital signs) and body weight will be taken by the study doctor or a qualified staff member. On the days you receive investigational drug, your vital signs will be taken before dosing and after dosing.
Electrocardiogram (ECG)	Several small, sticky pads will be placed on your chest, arms, and legs while you are lying down. A wire from each pad goes to a machine that makes a recording of your heart rhythm. Each time three ECGs will be taken within a few minutes (triplicate ECG’s). This test takes about 15 minutes in total and will be done on specified days during the study. On the first day you receive study drug, triplicate ECG’s will be taken before dosing and after dosing
MRI (Magnetic Resonance Imaging) Scan	MRI scans will be performed to look at the structure of your brain. MRI machines use magnets to produce images. You will be asked to lie still on a moveable table so that an MRI machine can take images.

	<p>An MRI differs from a PET (positron emission tomography) scan because it does not use radiation. The procedure will last approximately 50 minutes. You will receive up to 7 scheduled MRIs during the course of the study. You may be asked to have additional unscheduled MRI scans if you experience MRI evidence of ARIA-E and/or ARIA-H. ARIA stands for “Amyloid Related Imaging Abnormality” and is a finding on the MRI that shows a build-up of fluid and proteins in the brain (ARIA-E for oedema) or bleeding from small blood vessels (ARIA-H for haemorrhage).</p>
<p>PET Scan</p>	<p>In this study, the PET scan is used to take pictures of your brain tissues and the malfunctioning proteins that are thought to cause and worsen AD. These proteins are commonly referred to as beta amyloid and tau. However, these proteins are very small and hard to detect in the brain, so the PET scan requires a substance that is labelled with radioactive material that will stick to them and increase their visibility. You will be given an injection of this tracer into a vein through a cannula (narrow tube). After waiting approximately an hour for your body to absorb the tracer, you will be asked to lie still on a moveable table for approximately 30 minutes so that a PET machine can take pictures of your brain. Prior to PET scanning, a low-dose CT (computerised tomography) scan (a series of X-ray images) may be taken to make the PET scan measurements more accurate. This does involve a level of radioactivity which is described in more detail in the risk section.</p> <p>Any doctor who is responsible for your care can order an amyloid PET in a clinical setting; however, tau PET is only available to those who participate in research because it has not yet been approved by regulators. Both types of PET scans are offered as part of this research study. If you elect to participate in the optional longitudinal PET assessments (described below), you will help us understand how AL002 works in the brain throughout the study. In addition, your contribution will also help us understand the relationship between these proteins in the brain and how they affect your ability to remember things in your daily life.</p> <p><u>Amyloid PET</u>: At Screening/Baseline Visit, an Amyloid PET scan may be completed to look for amyloid plaques in the brain. At most you will receive one amyloid PET scan during the course of the study unless you agree to participate in the optional longitudinal Amyloid PET assessment described below.</p>



	<p><b>OPTIONAL</b> longitudinal Amyloid PET assessment: If you agree to participate in the optional additional Amyloid PET scans you will have a maximum of three Amyloid PET scans during the course of the study. If you experience evidence of ARIA you may be asked to have an additional Amyloid PET scan performed. Additional PET scans are optional, and you can choose not to participate.</p> <p><b>OPTIONAL Tau PET:</b> The Tau PET scan is an <b>optional</b> assessment that is similar to Amyloid PET in terms of the process but gives a picture of tau levels in the brain, a different protein. Before and after the scan, your vital signs may be measured. At most you will receive four Tau PET scans during the course of the study.</p>
Eye exams	<p><u>Visual Acuity:</u> You will be asked to read letters on an eye chart to help the study doctor determine how clearly you see.</p> <p><u>Optical Coherence Tomography (OCT) Scan:</u> OCT is an imaging technique that allows an eye doctor to take an image of the back of your eye. OCT uses a bright light to take a picture of the back of your eye and measures the thickness of the back of the eye to look for swelling.</p> <p><u>Fundoscopy:</u> The eye doctor will view the back of your eye using an ophthalmoscope, a handheld lens with a light held in front of your eye.</p> <p><u>Slit lamp examination:</u> The eye doctor will use a bright light to look at the inside of your eye in more detail using a binocular microscope called a “slit lamp”.</p> <p>For the eye exams your eye doctor may put drops in your eyes to allow your pupils to dilate (get bigger). You may have blurry vision for a short period of time after the exam until the effects of the drops wear off.</p>
Suicidality Testing: Columbia-Suicide Severity Rating Scale (C-SSRS)	<p>This is a questionnaire that is used to assess suicidal thoughts and behaviours. The study doctor or study personnel will ask you questions and document any issues you may have recently experienced.</p>
Lumbar Puncture	<p>Cerebrospinal fluid (CSF) is a fluid that provides protection to your brain and transports waste out of your brain. The brain normally has about 100-150 ml CSF and it re-fills every 6-8 hours. Your CSF sample will be collected to check how much AL002 is getting into your brain. It also lets us test biomarkers to see if we can detect a change in the proteins that are responsible for the development and worsening of Alzheimer’s disease.</p>

	<p>In this study, we will collect a small volume of CSF during a procedure known as a lumbar puncture (LP). First, we will take a small blood sample (3mL) to test your blood's clotting factors to make sure that the procedure will be safe for you. For this procedure, you will typically be lying down on your side or sitting up and leaning slightly forward to reduce the likelihood of headaches or side effects. Other side effects may include backache, irritation at the needle insertion site, dizziness, infection where the needle was inserted and bleeding into the spinal canal.</p> <p>If your study doctor decides that you can take part in the CSF collection, you will have a LP. A hollow needle will be inserted into your lower back to draw CSF from the spaces surrounding the spinal column. You will be given a local anaesthetic in this area to minimise discomfort.</p> <p>If you have evidence of ARIA-E and/or ARIA-H you may also be asked to have an additional LP. Additional LPs are optional and you can choose not to have one. LP may be required within 4-8 weeks of treatment discontinuation if you discontinue due to ARIA.</p> <p>If you are in Group 1, the LP procedure is required, maximum of 5 LP's will be performed.</p> <p>If you are in Group 2, the LP procedure is optional. A LP may be required at Screening Visit if you are in Group 2 to confirm the presence of a protein in the brain called amyloid beta.</p>
<p><b>Optional</b> Winterlight Lab Speech Assessment (WSLA)</p>	<p>You have a choice to take part in the <b>optional</b> Winterlight Lab Speech Assessment (WSLA). There will be at-site and at-home assessments. You can choose to participate in both types of assessments or to only participate in the at-site assessments. To participate, you need to be fluent in English, French, German or Spanish. If you agree to participate in the at-home assessments, you need to have a study partner to supervise/administer the speech assessment, have access to an iPad or iPhone, and have WiFi access in your residence or WiFi access in a private area where the testing can take place.</p> <p>You will be asked to complete the Winterlight assessment at home approximately every 4 weeks with study partner supervision and approximately every 24 weeks at the study site. The Winterlight assessment is an electronic assessment done on an iPhone or iPad. During the assessment, you will be asked to do things like describe</p>



pictures, name objects, read a short story and generate a list of words. Your study partner will guide you through the assessment, which will take between 15 and 30 minutes to complete.

If you consent to participate in the WLSA, your verbal responses to the assessment will be recorded, if you agree. Winterlight will also collect additional information including your ethnicity, number of years of education, country of birth, year you moved to your current country, and first language. The site will register you on the WLSA platform with your study code: the Sponsor will not have your email address or other directly personal identifiable data. If English is not your first language, Winterlight will ask when you learned it and how long you have been speaking it. Staff at Winterlight will have access to your recordings to transcribe them as well as check them for quality issues, including background noise or microphone problems. The data that are collected for this research will be coded so that you cannot be identified. All data will be kept on a secure, access-controlled server.

Winterlight will use your coded speech data to develop digital biomarkers for cognitive disease. These biomarkers and your data will be used by Winterlight for research, commercial and development purposes and will be retained by Winterlight in accordance with their Data Backup and Retention Policy. De-identified data from the Winterlight database may be shared with their contracted service providers, government agencies, researchers, and other third parties as may be required. Data in the database may also be shared so Winterlight can obtain market approval for new products resulting from this study. By signing this consent form, you consent to the collection, access, use and disclosure of your information as described above, and in order to conduct this research study. The results of this research study may be presented at meetings or in publications, but your identity will not be disclosed.

If you have questions about Winterlight's privacy policies or practices, the use of your data by Winterlight after the conclusion of the study, or if you wish to withdraw your consent to Winterlight's processing of your data at any time after the study, or have your data purged from Winterlight's systems, please contact the Sponsor's Data Protection Officer listed in the "How will your confidentiality be respected and the privacy of your personal information be maintained" section.

A complete and up to date version of Winterlight's Privacy and Security Notice is available at the following website:

	<a href="https://winterlightlabs.com/assets/docs/wll_privacy_notice.pdf">https://winterlightlabs.com/assets/docs/wll_privacy_notice.pdf</a>
--	---

<b>Laboratory Test and Biological Sample Collection</b>	<b>Description</b>
Blood samples for health testing (chemistry, haematology)	Samples of your blood will be tested to check your health. You will have approximately 15 mL (approximately 3 teaspoons) of blood taken for these tests. Chemistry samples are to test liver, kidney, muscle, and metabolic function. Haematology samples are to test the number and types of cells in your blood. Your study doctor may request additional blood samples to check your health before receiving the study drug or performing study procedures.
Blood Samples for blood clotting (coagulation)	Samples of your blood will be tested to measure how long it takes your blood to clot. This is used to help your study doctor assess your risk of bleeding or developing clots. You will have approximately 3 mL (approximately 3/4 teaspoons) of blood taken during the study.
Blood sample for HIV (human immunodeficiency virus) and hepatitis testing	A blood sample of approximately 13 mL (approximately 2 1/2 teaspoons) will be taken at the Screening Visit to test for HIV and hepatitis B and C (viruses that affect the liver). You will be informed of the test results. A positive test means that you may have been exposed to HIV or hepatitis. If you test positive, you may not be able to participate in the study.
Urine samples for health tests	Samples of your urine will be tested to check your health.
Pregnancy test	If you are a woman who can get pregnant, your blood will be tested for pregnancy at the Screening Visit. If you participate in the optional Tau PET assessment, a sample of urine will be collected at the study visits where images are obtained to test for pregnancy. To take part in this study, the pregnancy test must be negative. You will be informed of the results.
Pharmacokinetic (PK) test for AL002	On some dosing days, you will have 2 or 3 samples of your blood taken to see how much study drug is in your body, 1 before dosing and 2 after dosing (approximately 12 mL in total, approximately 2 1/2 teaspoons). At visits when you do not receive study drug, you will have approximately 4 mL (approximately 3/4 teaspoon) of your blood taken to see how much study drug is in your body. <b>_OPTIONAL:</b> If you participate in the optional PK assessment, you will have 3 samples of blood drawn. (Approximately 12 mL in total, approximately 2 1/2 teaspoons)

Antibody test for AL002	You will have approximately 4 mL (approximately $\frac{3}{4}$ teaspoon) of your blood drawn to determine if your immune system is reacting to the study drug.
Blood samples for biomarkers	Biomarkers are substances that can help to understand the disease, understand how the study drug affects the disease, and answer study questions. Your blood samples will be used to help understand how the study drug is working in your body. You will have approximately 10 mL (approximately 2 teaspoons) of blood drawn for biomarker testing.
Blood Sample for Amyloid Positivity	At the Screening Visit a blood sample of approximately 2 mL (approximately 1/2 teaspoon) will be taken to help describe the build-up of a protein in the brain called amyloid beta. The result will be used to determine whether you are suitable for participation in the study, and if you qualify for an amyloid PET scan or lumbar puncture. You may be required to fast (go without food and drink except for water) on the day of the test beforehand; the study staff will provide you the instructions.
Blood sample for testing of genes (genetic or genomic testing)	Genes are factors that you inherit from your parents that may influence your chances of developing a disease. You will be asked to provide a blood sample to assess APOE, a genetic marker that is related to your Alzheimer's disease symptoms. If this indicates you have two copies of the APOE e4 allele, then you will not be able to participate in this study. You will have maximum of approximately 20 mL (approximately 4 teaspoons) of blood taken for genomic testing.
<b>Optional</b> non-study related future research testing	If you agree, leftover blood and CSF from the samples collected during the study and images collected during the study may be used to help answer questions that are not part of the main study. If you do not agree, you can still take part in the main study. More information is below.
How much blood will be taken from me during each visit?	At most, the amount of blood taken at each visit will be approximately 56 mL (approximately 11 teaspoons).

<b>Study Drug</b>	<b>Description</b>
Receive study drug (AL002 or placebo)	You will be given the study drug every 4 weeks. The study drug (AL002 or placebo) will be given to you as a slow infusion into a vein (called an intravenous (IV) infusion) at the study site by a qualified study site staff member. The infusion will take

	approximately 60 minutes unless the study doctor decides, for your safety, to slow down or temporarily stop the infusion.
--	---

Due to the effects of COVID-19 as well as drug supply shortages worldwide, some of your study examinations may not be completed and you may not receive study drug as specified in the study protocol. Your study doctor or the study staff will maintain contact with you to monitor your disease and physical condition and provide you with guidance about what to do, as necessary. If you are not able to visit the study site, study staff may contact you to perform some procedures and assessments at your home and other procedures remotely by telephone or video, if locally approved. This makes it possible for you to interact with the study staff in a visual manner (e.g. Skype, FaceTime, Telehealth or another video system). It will help to oversee your safety remotely when you're unable to come to the study site. By signing this consent, you agree to be contacted remotely through video or telephone and to allow site staff to visit your home to complete some procedures, like weight, vital signs, blood draw and investigational drug infusion

If the visit cannot be completed on site (at the clinic), or there is limited availability of the required equipment to perform an assessment/procedure, or you need to reduce the amount of time on site, certain missed assessments may be completed at a future on-site visit.

If you experience any adverse event, you need to tell your study doctor or study staff right away. If you can no longer obtain study drug treatment or cannot undergo necessary safety tests, you and your study doctor will discuss your continued participation in the study.

### **Clinical Outcome Assessments Questionnaires (COAs)**

This study uses instruments that are commonly referred to as COAs. The COAs are questionnaires and most of them will be administered by your study doctor or other qualified study site personnel (called the interviewer) and you will be asked to respond to their questions. With your permission, we will ask someone who knows you well to be your study partner. We are not seeing you every day, so we rely on the information that a study partner provides to give us information about your daily tasks like taking care of yourself and how you are doing in your community. It is important for us to get information from both of you so that we can have a more accurate picture of how you are doing.

In addition to questionnaires, COAs also include cognitive tests. Cognitive tests measure aspects of your thinking that involve memory, language, attention, processing speed and in some cases your ability to problem-solve. For some parts you will be asked to do some tasks like drawing or counting. The interviewer will enter your answers on a secure tablet. The data will be encrypted and transferred electronically to the United States.

For 3 of the COAs (Clinical Dementia Rating, Repeatable Battery for the Assessment of Neuropsychological Status, and Alzheimer’s Disease Assessment Scale - Cognitive Subscale), you and your study partner’s interviews will be audio recorded and sent in a secure way to a data company (see additional information below) for quality control and training purposes. This data company specialises in measuring thinking ability and is working in partnership with the Sponsor.

More information about the processing of your data in the recorded interviews can be found further below in the section titled, “How will your confidentiality be respected and the privacy of your personal information be maintained?”

Each of the COAs are described below in more detail.

<b>Clinical Outcome Assessments (COA)</b>	<b>Description</b>
<b>Clinical Dementia Rating</b>	Performed to assess your memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. This will be done through interviews with you and your study partner.
<b>Mini-Mental State Examination</b>	Performed to assess cognitive impairment (impairment in the brain).
<b>Repeatable Battery for the Assessment of Neuropsychological Status</b>	A collection of tests of several areas including memory, language, attention, and visual skills.
<b>Alzheimer’s Disease Assessment Scale - Cognitive Subscale</b>	Performed to measure any disturbances of memory, language, how you perform tasks, attention, and other cognitive (brain) abilities
<b>Alzheimer’s Disease Cooperative Scale – Activities of Daily Living – Mild Cognitive Impairment Scale</b>	Performed to assess the activities you normally perform as part of daily living. This will be done through interviews with your study partner.

If you are not familiar with any of the procedures, tests, or assessments that have been described above, please ask your study doctor to explain how they are performed.

### **Screening period**

Your study doctor will invite you to come to the study site for a Screening Visit to see if you are able to take part in this study. If you agree to take part in the study, at your Screening

Visit(s), the following procedures will be performed to determine whether you are suitable for participation in the study. The screening period may last up to 8 weeks. In some cases, the screening period may be extended for an additional 4 weeks and it may be necessary to repeat some of the screening procedures.

- You will be required to sign this Informed Consent Form.
- You will be asked to provide demographic information, medical history, social history, and current health and medications including any supplements you may be taking.
- You will have detailed physical and neurological examinations, and your height and weight will be recorded.
- Vital signs will be measured.
- Blood will be collected to check your general health, levels of biomarkers in your blood, for HIV, hepatitis B testing, and genomic testing. You may be required to fast (go without food and drink except for water for at least 8 -10 hours) prior to some blood tests (If you are in Group 2 and agree to the optional lumbar puncture, extra blood will be taken).
- If you are able to get pregnant, your blood will be tested during the Screening Visit to check that you are not pregnant.
- Urine will be collected to check your health.
- Clinical Outcome Assessments (questionnaires) will be administered to you and your study partner.
- Eye exams will be performed.
- ECG testing will be conducted to check your heart rhythm.
- MRI scans of the brain will be performed.
- An Amyloid PET or a lumbar puncture will be performed unless you have a previous positive Amyloid PET. If you are in Group 1, you will have a lumbar puncture regardless of a prior positive Amyloid PET.

If you meet all study requirements, you will be asked to return to the study site for Day 1 to receive the first dose of study drug (AL002 or placebo). If you agree to participate in some of the optional assessments, you will be asked to attend a pre-dose baseline visit before visit Day 1.

### **What is expected from you?**

If you decide to take part in this study, there are some rules you must follow. Some of the rules are listed below. There could be other rules that your study doctor will review with you. You must agree:

- To follow the study rules.
- To commit to the time required to keep appointments.
- To tell the study doctor about your complete medical history.
- To report any new problems, illnesses, or changes in medication during the study. If you do not tell the study doctor everything you know, you may be putting your health at risk.



- To refrain from taking any medications during the study that might interfere with the study drug, procedures, or study results without talking to your study doctor first.
- To not get pregnant or get someone pregnant during this study. You must use the acceptable contraceptive methods if you or your sexual partner is capable of becoming pregnant.
- To follow all instructions given to you while you are taking part in this study. If you do not, you may no longer be able to take part in the study. If you are unsure about what you are supposed to do, ask your study doctor.
- To have the availability of a person (“study partner”) who has frequent and sufficient contact with you (at least 10 hours per week) and who can provide accurate information regarding your memory and daily functioning as well as your overall health throughout the study.
- To not donate blood during the study and for 1 year after the last dose of study drug.
- Male participants are not allowed to donate sperm from the screening visit until 12 weeks after the last dose of study drug.
- This study has certain diet and lifestyle restrictions that must be followed throughout the study.
  - Refrain from using marijuana or other cannabinoids (such as THC) other than cannabidiol (CBD) within 72 hours prior to study visits with cognitive and behavioural assessments. You should talk to your doctor if you are taking any medications that impair your thoughts, as these may also need to be stopped before study visits with cognitive and behavioural assessments.
- You cannot take part in another study using another study drug while you are taking part in this study.

### **What will happen at the end of the study?**

After the study ends, study drug will not be available to you unless you are invited to participate in another study with AL002. After the study drug is stopped, your study doctor will decide what medical treatment you should receive. If you discontinue the study drug early, you may be asked to attend your study visits and complete the scheduled procedures as planned. This will allow you to continue your participation even if you are no longer taking the investigational drug. In the event you decide not to continue your participation in the study, then you will be asked to return to the study site within 4 weeks after your last dose of study drug for an Early Termination Visit to check your health.

The Sponsor will provide your study doctor with a summary of the study results, and they will be encouraged to share these results with you. If you would like to receive a copy of these results, please contact your study doctor in writing to request this. It may take a little while for you to receive these results, as the study data needs to be analysed and be sent for publication, as needed.

## **What are the potential risks and discomforts?**

All drugs may cause certain side effects and discomforts. The most common discomforts are listed below. There may also be side effects and discomforts that are not yet known.

### **Risks of AL002:**

AL002 is an investigational drug, with some identified risks such as Amyloid Related Imaging Abnormality (ARIA). These are discussed in further detail in the sections below. In addition, AL002 may be associated with risks that are not yet known. In addition to the risks that we have identified below, there is a possibility of serious illness, hospitalisation or death. Therefore, AL002 risks will be carefully monitored and managed throughout the duration of the study.

#### Risks from AL002-1 and AL002-2 human clinical studies:

In study AL002-1 a total of 53 healthy adult participants received single doses of AL002. The most frequent side effect reported by healthy participants exposed to AL002 was headache in 19 out of 53 participants. Other side effects in 2 or more healthy participants exposed to AL002 include nausea, upper respiratory tract infection, pain where needles have entered the skin, back pain, vomiting, dizziness, tingling sensation on the skin, and headache after lumbar puncture. A side effect of sensitivity to light was observed in 1 healthy participant exposed to AL002 and resolved in the same day without needing any treatment.

The current study that you are consenting to, AL002-2, is ongoing and remains blinded. This means that we still do not know who is receiving AL002 or placebo. Of the first 118 participants with AD who have taken at least 1 dose of AL002 or placebo, 85 participants have reported one adverse event, or side-effect. Most have been mild but there are others that were moderate and severe. Side effects included infusion-related reactions, vomiting, nausea, and fatigue. Another side effect associated with AL002-2 that has been reported is commonly referred to as ARIA which we will describe in the sections below.

#### *What is ARIA?*

ARIA or “Amyloid Related Imaging Abnormalities” refers to findings on an MRI scan of the brain that indicate a build-up of fluid and protein or small areas of bleeding within the brain (ARIA-E stands for oedema or swelling type abnormalities while ARIA-H stands for haemorrhagic or bleeding type abnormalities).

In most cases, ARIA does not result in symptoms and can only be detected by looking at pictures of your brain with MRI. Some people have symptoms such as: headache, confusion, dizziness, nausea, fatigue, vomiting, blurred vision, trouble with walking, and seizures. Depending on the severity of your symptoms, ARIA could lead to hospitalisation or death. In our study, most cases of ARIA have resolved or stabilised with and without treatment.

*ARIA-E on MRI in the AL002-2 study usually occurs in the first 3 months of treatment (90% as of April 2022) and has been mostly without symptoms (except 3 serious ARIA cases with symptoms) and typically goes away on MRI over a period of ~ 6-12 weeks (60% as of April 2022). What has been seen with ARIA-H has been similar, although ARIA-H typically continues to be seen on MRI after the initial observation and tends to stay visible rather than go away.*

*Has ARIA occurred in this study?*

- ARIA-E
  - Yes, overall, 30 of 110 (27%) participants who had received at least 1 post-baseline MRI have experienced ARIA-E.
  - The ARIA-E observed on MRI were typically temporary and improved in an average of 72 days.
- ARIA-H
  - Yes, overall, 26 out of 110 (24%) participants who had received at least 1 post-baseline MRI have experienced ARIA-H
    - Many patients who had ARIA-H also had ARIA-E.
    - The brain changes seen on MRI that indicated ARIA-H, typically stabilised on later follow up MRIs
  - Three participants with ARIA-H experienced side effects that were considered clinically serious. These included:
    - One participant who experienced confusion, speech difficulties, weakness, and a seizure. The patient improved after treatment with a steroid medication.
    - A second participant who experienced headaches, difficulty walking, and a possible seizure. This patient also improved after treatment with a steroid medication.
    - A third participant who experienced brain swelling (ARIA-E) dizziness, weakness, and impairment of vision. This patient similarly improved after treatment with a steroid medication.
- All 3 of these participants had two copies of the APOE e4 gene allele (APOE e4 homozygotes). Consequently, this study is no longer enrolling APOE e4 homozygotes.

*How this study will attempt to minimise the risk of serious ARIA*

- To minimise the risk of ARIA for participants in this study, we will not include people who have two copies of the APOE e4 gene allele (APOE 4 homozygotes).
- The investigator and study personnel will do a comprehensive examination and will review your brain images to see if you are healthy enough to participate in this study. If the examination or your brain images suggest that you may be at increased risk of ARIA, you will not be invited to participate in this study.
- You will have brain MRIs regularly throughout the study and before your AL002 dose is increased so that we can monitor your brain MRI scans for any signs of ARIA.

*How will the participants be monitored for ARIA in this study?*

- The dose of AL002 will be increased in a stepwise fashion each month for those participants receiving the middle or high dose. Based on studies of other drugs being tested in AD called anti-amyloid antibodies in which ARIA was observed, slowly increasing the dose over time may reduce the risk and severity of ARIA in AD patients. The current study is testing whether this may also be the case in studies of AL002.
- All participants will have MRI scans performed monthly for the first three months of treatment, and at various times throughout the study. These scans will be reviewed by a doctor who specializes in looking at ARIA on brain MRI and those results will be given to your study doctor approximately 5 days after your scan.
- If, at any time during your study participation, you should experience new symptoms, such as headache, confusion, dizziness, nausea, fatigue, blurred vision, speech difficulty, weakness, difficulty walking or seizures, please report these symptoms to your study doctor immediately.
- The study site may also contact participants throughout the study to ask how they are feeling.

*What will happen if I experience ARIA?*

- If you experience ARIA you will receive follow-up MRIs every 4-6 weeks until the ARIA is resolved or stable.
- Depending on how serious the ARIA is, you may be withdrawn from study treatment, or dosing may be paused, and treatment might restart after ARIA resolution or stabilisation. You will have a conversation with your doctor about how to manage this.

### Uveitis Risks

In the tests on animals, some animals showed inflammation of the eye called uveitis. Uveitis is a type of inflammation inside the eye. Sometimes it can cause eye redness, pain, blurry vision, and light sensitivity, and may affect one or both eyes. In some cases, if the inflammation is serious and if not treated, it can lead to loss of vision. Early diagnosis and treatment are important to prevent complications of uveitis. If you develop any of the above symptoms or a change in your vision, you should immediately contact your study doctor as you may need to be examined by an ophthalmologist (eye doctor).

### Risks of Study Procedures

- **Blood Collection:** The risks involved in collecting a blood sample from a vein may include temporary discomfort at the site where the blood sample was taken, possible

bruising, redness and swelling at the site, bleeding at the site, a feeling of light-headedness when the blood is taken, and, rarely, infection.

- ECG: As a result of the patches that are put on your skin when performing the ECG, there is the possibility of a rash or minor skin irritation.
- Lumbar Puncture: A lumbar puncture is a relatively safe procedure, but there are complications that may occur when performing a lumbar puncture. A small amount of CSF can leak from the needle insertion site into the spine and nearby tissues. This can cause headaches after the procedure. Most headaches resolve spontaneously and are mild; occasionally a severe headache can occur due to low pressure caused by a leak of CSF from the needle insertion site. This usually resolves with bed rest and fluids over a few days. If it persists for a week or more, then it may require admission to hospital for a procedure known as a blood patch, where a sample of your own blood is inserted via a needle into the spine to stop the CSF leak. There is a slight risk of infection because the needle breaks the skin's surface. You may experience temporary numbness or pain of your legs or lower back. Bleeding may occur in the spinal canal. There may be other risks depending on your medical conditions, which need to be discussed with the doctor before the procedure.
- **Imaging Scans:** Some patients find the inside of the scanner to be uncomfortably small. You must remain still throughout the procedure. You can discuss techniques or medications to make the experience easier for you.
  - **MRI scan:** The MRI environment involves a strong magnetic field. While there are no known health hazards from temporary exposure to the MRI environment, the magnetic field will attract magnetic objects. MRI scans are not recommended for individuals with metal implants such as a pacemaker, metal plates or pins from surgical procedures, and artificial heart valves. You should tell the medical staff if you think you have any metal in your body. The magnetic fields create loud, knocking noises. Ear protection will be provided. They may also cause twitching sensations or a slight increase in body temperature.
  - **Amyloid and OPTIONAL Tau PET scan:**
    - If you take part in this study, you will have several PET/CT scans. All of these will be extra to those that you would have if you did not take part in the trial. These procedures use ionising radiation to form images of your brain to provide your doctor with other clinical information. Ionising radiation may cause cancer many years or decades after the exposure.
    - We are all at risk of developing cancer during our lifetime. 50% of the population is likely to develop one of the many forms of cancer at some stage during our lifetime. Taking part in this study will increase the chances of this happening to you to about 50.2 %.
    - There is a small but increased risk of harm to an unborn child from the radiation exposure you will receive as part of this study, you should therefore not participate in this study if you are pregnant.



- You may hear buzzing and clicking noises during the scan. You will need to have an injection of a radioactive tracer into your vein, and some people may find this uncomfortable. Some people have pain, redness, or swelling where the injection was given. Rarely, people may have an allergic reaction to the tracer. There is a small amount of radiation in the injection, but it goes away very quickly. This study involves up to 4 Amyloid PET scans (one that may be required at the Screening Visit, two optional ones at subsequent visits, plus one that will be offered as optional in the event of MRI confirmed ARIA) and optionally up to 4 tau PET scans (one at baseline and up to three at subsequent study visits) over approximately 2 years. Prior to PET scanning, a low-dose CT scan (a series of X ray images) may be used to help make the PET scan measurements more accurate.
- Risk of Developing Anti-drug Antibodies: Your body's immune system has the ability to react against anything foreign or not exactly like your own tissues and organs. When this reaction occurs due to the presence of a medication, it is called "immunogenicity." It is often due to antibodies that your immune system makes against the medicine or the molecule that is being given. This type of immunogenicity reaction can occur without being felt or can cause various types of side effects, including some that are severe. Immunogenicity reactions are like allergic reactions that can range from an itchy rash to shortness of breath, swelling, and low blood pressure. The antibodies can block AL002 from working or they can make AL002 stay in your body longer and cause more severe side effects.
- Infusion Risks: There are complications associated with delivering fluids and medications through an intravenous catheter. These may include swelling, discomfort, and tenderness at the site of the catheter or along the vein. Infection may occur causing redness and discharge at the site with an elevated temperature. Infusion-related reactions include immediate allergic reactions, which can be severe and life threatening. These reactions are experienced by patients during the infusion of monoclonal antibody therapy and/or within hours of an infusion. Symptoms can include flushing, difficulty breathing, bronchospasm, reddening of the face, changes in heart rate and blood pressure, sudden tight feelings in your chest, back pain, fever, hives, swelling, nausea, and all types of rashes. Your study site staff will observe you for these symptoms and signs and will have emergency equipment nearby in case you have a severe reaction. Premedication with antihistamines, acetaminophen, or other medications may be used to help prevent infusion reactions and can be discussed with your doctor.
- Eye Exam Risks: You may experience mild discomfort while undergoing the eye exams. For the slit lamp exam and for OCT, the drops that dilate your pupils may make your eyes sensitive to light and your vision blurred for a few hours afterward.
- Allergic Reactions: An allergic reaction is possible, as it is with any foreign drug being introduced to the body. The allergic reaction may include rash or hives. Anaphylactic shock, a serious potentially life-threatening allergic reaction resulting in extremely low



blood pressure, loss of consciousness, coma, and possibly death, is possible but considered unlikely to occur. You will be monitored closely for these allergic reactions and will be treated immediately should one occur.

- Questionnaires: Completion of questions about your thoughts on suicide may cause some anxiety and distress. Referral to a support person or professional is available should you desire.
- Privacy risks: Your privacy is important to Sponsor and Sponsor takes precautions to protect your privacy, but cannot guarantee that your identity will never become known. It is possible that there could be security breaches of the systems used to store the codes linking your genetic and personal information to you. There may also be other privacy risks that Sponsor has not foreseen.
  - Knowing the genetic information obtained in this study may have an impact on you or your family members.

## Are there any reproductive risks?

### Women:

It is not known whether AL002 may affect an unborn child or breastfeeding infant. For this reason, if you are pregnant or plan to become pregnant, or if you are breastfeeding, you may not participate in this study. If you are capable of becoming pregnant, you must use an acceptable method of birth control from screening until 12 weeks after your last dose of the study drug. Birth control methods considered acceptable for this study include using hormonal contraceptives or an intrauterine device **combined** with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom or being the sole sexual partner to a vasectomised male. Vasectomised males must have received medical assessment of surgical success. Also, total abstinence, in accordance with the lifestyle of the participant, is acceptable.

If you become pregnant during your participation in the study, immediately inform your study doctor. You will no longer be able to receive study drug. However, data and information about your pregnancy and the outcome of the pregnancy may be collected. Pregnancies occurring within 8 weeks after the last dose of the study drug must also be reported to the study doctor. The study doctor will arrange for you to be counselled by a specialist physician, in order to discuss the risks of continuing with the pregnancy and the possible effects on the unborn baby. Monitoring of your pregnancy will continue until the outcome is known.

### Men:

It is not known whether AL002 may affect your sperm or an unborn child. For this reason, you must use an acceptable method of contraception with female partners who are capable of becoming pregnant throughout the entire study and for at least 12 weeks

after the last dose of study drug. An acceptable method of contraception is defined as using a condom and in addition the female partner must use hormonal contraceptives or an intrauterine device. Vasectomised male participants should have received medical assessment of surgical success. If your partner becomes pregnant, you must tell your study doctor immediately. They will talk with you about what you and your partner should do. Your partner may be requested to sign a separate informed consent form for the collection of data about the pregnancy and the outcome of the pregnancy, if required by country regulations.

### **What are the possible benefits of taking part?**

You may not personally benefit from taking part in this study. Studies are a way for doctors to see if a drug is useful in fighting a disease. However, by taking part in this study your health will be monitored closely at study visits and you will provide new information that may benefit other people in the future.

### **Are there any alternative treatments?**

If you do not want to take part in the study, there are other medicines available to treat the symptoms of your Alzheimer's disease to some extent. You do not have to be in this study to receive treatment for your Alzheimer's disease. The study doctor will explain the alternative treatments that are available to you and discuss with you the risks and benefits of these alternative treatments.

### **Will you be informed if new information becomes available during the study?**

Your study doctor will inform you and your study partner and your Legal Representative (if applicable) in a timely manner of any new information learned during the study that may affect whether you or your study partner would like to continue participating in the study or not. If you decide to continue in the study after reading this new information, you may be asked to sign an updated consent form.

### **What happens if you change your mind?**

Your participation in this study is voluntary. You do not have to take part, and you may discontinue your involvement at any time without penalty or loss of benefits to which you are otherwise entitled. If you decide to leave the study before the last study visit, tell the study doctor and follow his or her instructions. It may be helpful if you could explain your reasons. You may receive standard treatment, and no prejudice will be shown toward you regarding medical care or participation in future research.

The results of this study will be published, but the data will be anonymous, i.e. you will

not be identified in any report or publication. Your study doctor will be given a copy of the report or publication at the end of the study.

In addition, your study doctor or the Sponsor may withdraw you from the study for your own safety, even if you wish to continue to participate, for example, under the following circumstances:

1. You do not follow the rules of the protocol.
2. You stop participating in the study and you stop responding to the study site.
3. You have a serious or intolerable side effect (adverse event) that, in the study doctor's opinion, requires withdrawal from the study.
4. You use a nonpermitted medication.
5. If you participate in any other interventional trial during the duration of this trial.
6. You are a female and become pregnant.
7. You experience a moderate to severe allergic reaction related to the study drug infusion.
8. The study is stopped by the study site, the Sponsor, an ethics committee, or a health authority.

If for any reason your participation in the study stops, the reason will be explained to you. For your own safety, you will be asked to return to the study site for final health checks. The study doctor will discuss any medical issues that may arise with you, discuss alternative treatment with you, and help you make arrangements to receive alternative medical care.

### **Expenses and payments**

You will not receive payment for participating in this study. You will receive the study drug and all study-related procedures at no charge.

You and your study partner may be reimbursed for any reasonable and actual travel expenses for attending all required study visits (bus/train/taxi fares/flights/hotels). You will be reimbursed for such costs after receipts have been received for these expenses.

### **Who is funding this research?**

The Sponsor will be funding this study. The Sponsor will pay the hospital or clinic to conduct this study.

### **What if there is a problem?**

## Complaints

If you have a concern about any aspect of this study, you should ask to speak with the researchers who will do their best to answer your questions 020 3355 3536. If you remain unhappy and wish to complain formally, you can do this through the Re:Cognition Health complaints procedure [compliance@re-cognitionhealth.com](mailto:compliance@re-cognitionhealth.com). We recommend that you obtain a copy of your hospital's complaints procedure or policy if you intend to make a complaint.

## Harm

Alector Inc. will provide compensation for any injury caused by taking part in this study in accordance with the guidelines of the Association of the British Pharmaceutical Industry (ABPI).

Alector Inc. will pay compensation where the injury probably resulted from:

- A drug being tested or administered as part of the trial protocol
- Any test or procedure you received as part of the trial

Any payment would be without legal commitment. (Please ask if you wish more information on this)

Alector Inc. would not be bound by these guidelines to pay compensation where:

- The injury resulted from a drug or procedure outside the trial protocol
- The protocol was not followed.

*Copies of these guidelines are available from your study doctor on request.*

## How will your confidentiality be respected and the privacy of your personal information maintained?

The study site will record basic personal details about you, including your name, contact details, gender, height, weight and racial origin (to be used only for clinical purposes), as well as information on your medical history, and clinical data collected about your participation in the study. The following people may also access these records:

- Study monitors and auditors, who may work for Alector Inc or its authorised agents, who check that the study is being performed correctly and that the information collected about you is accurate;
- Ethical committee that approved this study and ensures that your rights and well-being are safeguarded;
- National and international regulatory authorities involved in keeping research safe for participants;
- Clinical trial recruitment company if you were referred to the study by such a company, for analytical purposes and so they may be compensated.

To ensure privacy, your name and other directly identifying information will not be attached to records or samples released to Alector Inc. and its service providers for research purposes. Instead, you will only be identified by a code. Only the study doctor and authorised personnel will be able to connect this code to your name, by a list that will be kept securely by the study site for 15 years. Your year of birth may also be recorded to help identify your study record. Your coded data will be forwarded to Alector Inc. and its service providers for activities related to the study e.g. laboratory analysis. A list of companies to whom your coded information is transferred is available from Alector Inc. via your study doctor.

Under the Data Protection Act 2018, Alector Inc. makes important decisions on how your information collected for the research project are used and disclosed and is responsible as 'controller' for ensuring that the rules of this law are followed. Alector Inc. has appointed My Data Trust as its 'representative' to fulfil its obligations under this law. The study site will have similar responsibility in respect to the handling of data in your medical files at site.

To the extent there is no conflict with the purpose of the study, you have the right to access, through your study doctor, all the information collected about you and, if applicable, ask for corrections. You may have the additional rights to object to how your information is being handled, request deletion of your data, restrict aspects of the processing of your information or ask for a copy of your data to be provided to you, or a third party, in a digital format. Note however, in order to protect the scientific integrity of the study, the treatment you receive in this study needs to remain unknown (= blinded) until the study data is analysed.

You also have the right to complain about how your information is handled to a supervisory authority that is responsible for enforcing data protection law. In the UK, this is the Office of the Information Commissioner.

Recipients of your information may be in countries that do not provide the same standard of legal protection for your information as in the United Kingdom, raising the risk that you will not be able to enforce the above rights and recipient organisations may not be legally required to fully secure your data. Certain international recipients of your information may have signed special contracts to provide legal protection for your transferred information (e.g. so called "Standard Data Protection Clauses"). In any event, all parties involved in the study are required to maintain your confidentiality.

Your information is collected, used and disclosed in the interest of the Alector Inc. conducting scientific research. You are asked to consent to various uses and disclosures of your information at the end of this form.

If you should withdraw from the study, data collected prior to your withdrawal may still be processed along with other data collected as part of the study. Normally no new

information will be collected for the study database unless you specifically consent to that. However, the law does require that any side-effects you may suffer are documented. You have the right to require that any previously retained samples are destroyed.

This study may only be performed by collecting and using personal information on study participants as described in this form, therefore you may only participate in the study if you agree to the collection and use of your information as described here.

If you have any questions, comments or complaints about how your information is handled in this study, or wish to obtain a copy of the Standard Data Protection Clauses, you should firstly contact your study doctor who will be able to direct your query where appropriate to staff responsible for data protection at Alector, Inc. or site, including the site Data Protection Officer.

### **Remote Data Verification**

The COVID-19 pandemic creates circumstances where it is difficult or impossible for study monitors, auditors and those other individuals mentioned in this form to access the study site to check that the study is being performed correctly and that the information collected about you is accurate. Remote and digital solutions may be adopted to allow the study to continue in these circumstances. Such solutions will involve your personal information collected for the study being handled and disclosed in new ways. These solutions may include the following:

- Information from your medical file may be “redacted” and shared with remote based study monitors, auditors and other individuals. Redaction means that your identifying information will be removed and replaced with your code.
- The study site may provide study monitors, auditors and other individuals with secure remote access to their electronic systems.
- Certain sections from your medical file may be shared by the study team with the study monitors, auditors and other individuals using a video system.

In all cases, the study site and the study monitors, auditors and other individuals will implement technical and organisational controls to ensure that your confidential personal information is protected. Full details on how your personal data is respected in the study, and the rights you have in respect to your study data, are set out in this study Informed Consent Form. You may withdraw your consent to the usage of these remote and digital solutions at any time.

### **What will happen to any samples I give?**

Your biological samples may be collected, processed and reported as necessary for the purposes of the study. Collected clinical samples will be stored at the central lab, and/or at sponsor designated lab vendor locations as listed below. Samples may be sent outside of the UK for analysis and storage.



Meso Scale Discovery -16020 Industrial Drive, Gaithersburg, MD 20877, US

Quanterix -900 Middlesex Turnpike, Building 1, Billerica, MA 01821, US

Covance Translational Biomarker Solutions = 671 South Meridian Road, Greenfield, IN 46140, US

ICON Laboratory Services - 123 Smith Street, Farmingdale, NY 11735, US

Blueprint Genetics - 2505 3rd Ave, Suite 204, Seattle, WA 98121, US

Somalogics - 2950 Wilderness Place, Boulder, CO 80301, US

C2N Diagnostics - 20 South Sarah Street, Saint Louis, MO 63108, US

Covance Central Laboratory Sàrl Services - Rue Moïse-Marcinhes 7, 1217 Meyrin, Switzerland

PPD Central Laboratories - Lozenberg 19, BE 1932 St. Stevens Woluwe, Brussels, Belgium

Some of the samples obtained from you will be frozen and stored. This is a requirement of the study. Your stored samples and the information collected about you during the study may be used by the Sponsor, its collaboration partner and research partners to perform analyses during the course of the study. At the end of this study, your samples may be held in storage by the Sponsor for up to 10 years. You have the right to be informed of any plans for new analyses on retained identifiable samples that are not currently foreseen, and you have the right to refuse further analyses.

You will be asked to indicate at the end of this Informed Consent Form if you agree to your samples being retained for optional future testing to help answer questions that are not part of the main study and further answer questions about the study drug, Alzheimer's disease, and related diseases. **This is optional.** You can always withdraw your consent. The samples obtained from you will then be destroyed. If your samples have already been analysed, the results will still be used. If you do not agree to optional future research, you can still participate in this study.

### **Has the study received medical or ethical approval?**

All research in the UK is looked at by independent group of people, called a Research Ethics Committee to protect your interests. This study has been reviewed and given favourable opinion by the London-Brent Research Ethics Committee.

### **Involvement of the General Practitioner/Family doctor (GP)**

Your general practitioner (GP) or family doctor will be notified of your involvement in this study. They will be asked to pass relevant information about your health status and medication changes to the study doctor.

**Who can you contact with further questions?**

You may ask questions about this information sheet and consent form or the study at any time (before or during the course of the study). If you have additional questions, or experience a research-related injury, contact the study doctor Dr. Emer Macsweeney or the study support staff on 0117 462 3600.

For any questions about your rights as a research participant, please direct enquiries to: [clinicaltrials@re-cognitionhealth.com](mailto:clinicaltrials@re-cognitionhealth.com)

The Sponsor has appointed MyData-TRUST as its Data Protection Representative (DPR) in the UK located at Waldeck House, Lyne Lane, Chertsey, KT16 0AW .

The Sponsor has also appointed a Data Protection Officer (DPO) that you can contact by phone on (+44) 56 0375 0073 and by mail at [gb.al002-2@mydata-trust.info](mailto:gb.al002-2@mydata-trust.info)

A description of this study will be available on <https://www.clinicaltrials.gov> (as required by US law) and <https://clinicaltrialsregister.eu>. These websites will not include information that can identify you. At most, these websites will include a summary of the results. You can search these websites at any time. These websites only show data in English, but you can request information from the study staff at any time and have access to data that are publicly available.

Do not sign this consent form unless you have had the chance to ask questions and have received satisfactory answers to all of your questions.

If you agree to participate in this study, you will receive a signed and dated copy of this information sheet and consent form for your records.

Thank you for taking the time to read this information.

## CONSENT FORM

**Study Title:** A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease

**Principal Investigator** \_\_\_ **Dr. Emer MacSweeney**

**Participant Number** \_\_\_ **22-0413-** \_\_\_ **Participant Initials** \_\_\_\_\_

<b>Statement of Consent</b>	<i>Please initial box:</i>
I confirm that I have read and understand the participant information sheet for the above study. I have had the opportunity to consider the information, ask questions and I am satisfied with the explanations provided	
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason and without my medical care or legal rights being affected	
<p>What will happen to your data? By signing this form you provide consent for your information to be collected, used and shared as described:</p> <ul style="list-style-type: none"> <li>• The authorised representatives of Alector Inc., the Ethics Committee and regulatory authorities' inspectors may have direct access to your medical records.</li> <li>• Study data, including your coded medical information, may be retained and later used for further research into your medical indication, unless you object.</li> <li>• Study data may be transferred to other countries for study purposes, including countries not providing the same standard of legal protection for your personal information as in the European Economic Area</li> </ul>	
I understand that my personal data (including my medical records and coded data) will be processed in connection with the study and as detailed in this Informed Consent Form.	
I specifically agree to my personal information and blood samples collected during the study being sent outside the European Economic Area as described in this information sheet	
I agree to my GP being informed of my participation in the study as described in this information sheet	
I understand that I and or my legally authorised representative will receive a copy of this signed and dated information sheet and consent form	

I understand that in extenuating circumstances certain missed assessments may be performed remotely via telephone/video if locally approved or moved to a following on-site visit.	
I voluntarily agree to take part in this study	

I consent to the use of my coded medical information for future medical or pharmaceutical research.

**Please initial One**

\_\_\_\_\_ **YES**

\_\_\_\_\_ **NO**

The Sponsor would like your permission to have study monitors, auditors and other individuals review your medical records remotely (outside the facilities of the study site, either by granting secure access to the electronic systems or via a video system):

I agree to have my medical records reviewed remotely by monitors, auditors and other individuals as described in this form.

**Please initial One**

\_\_\_\_\_ **YES**

\_\_\_\_\_ **NO**

## **OPTIONAL FUTURE RESEARCH**

You have a choice to take part in future research. If you decide not to take part in future research, you can still take part in the main study. If you agree, your CSF and blood samples and your images will be retained and may be used by the Sponsor, collaboration partner and other researchers for future testing and will be used to help answer questions that are not part of the main study and further answer questions about the study drug, Alzheimer's disease, and related diseases. You can always withdraw your consent. The samples and images obtained from you will then be destroyed. If your samples or images have already been analysed, the results will still be used.

**Please Initial one:**

I agree to allow my CSF and blood samples collected during this study to be stored and used for future research outside of the main study.

\_\_\_\_\_ **YES**

\_\_\_\_\_ **NO**

### CONSENT FORM Contd

**Study Title:** A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease

**Principal Investigator** \_\_\_\_\_ **Dr. Emer MacSweeney**

**Participant Number** \_\_\_22-0413-\_\_\_\_ **Participant Initials** \_\_\_\_\_

I agree to allow my images collected during this study to be stored and used for future research outside of the main study.

\_\_\_\_\_ **YES**

\_\_\_\_\_ **NO**

### OPTIONAL SPEECH ASSESSMENT

If you do not want to participate in the speech assessment, you will still be able to participate in this study.

**Please Initial one:**

\_\_\_\_\_ **YES**, I agree to participate in the optional speech assessment including the on-site and at home assessments

\_\_\_\_\_ **YES**, I agree to participate in the optional speech assessment but only in the on-site assessments

\_\_\_\_\_ **NO**, I **do not** want to participate in the optional speech assessment. I am still allowed to take part in the study.

I consent to the use of my coded medical information for future commercial purpose performed by Winterlight Labs.

**Please initial one;**

\_\_\_\_\_ **YES**

\_\_\_\_\_ **NO**

### **CONSENT FORM Contd.**

**Study Title:** A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease

**Principal Investigator** \_\_\_\_\_

**Participant Number** \_\_\_\_\_ **Participant Initials** \_\_\_\_\_

### **OPTIONAL FOR PHARMACOKINETIC ASSESSMENT**

**Please initial one;**

\_\_\_\_\_ **YES**, I agree to participate in the optional pharmacokinetic assessment

\_\_\_\_\_ **NO**, I do not want to participate in the optional pharmacokinetic assessment; I am still allowed to take part in the study

### **OPTIONAL LUMBAR PUNCTURE FOR CSF [spinal fluid] ASSESSMENT**

For participants in Group 1 the lumbar punctures for CSF assessment are required.

**Please initial one;**



\_\_\_\_\_ I am a **Group 1** participant; I know that the lumbar puncture assessments for CSF are required. If I do not want to have lumbar punctures, I can't take part in this study.

\_\_\_\_\_ I am a **Group 2** participant and **I AGREE** to participate in the optional lumbar puncture for CSF assessment for a maximum of 4 lumbar punctures

\_\_\_\_\_ I am a **Group 2** participant; I **DO NOT** want to participate in the optional lumbar puncture for CSF assessment. I am still allowed to take part in the study.

## OPTIONAL LONGITUDINAL AMYLOID PET ASSESSMENT

### CONSENT FORM Contd.

**Study Title:** A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease

**Principal Investigator** \_\_\_\_\_ **Dr. Emer MacSweeney**

**Participant Number** 22-0413- \_\_\_\_\_ **Participant Initials** \_\_\_\_\_

If you do not want to participate in the optional longitudinal Amyloid PET assessment and do not want to have additional Amyloid PET scans, you will still be able to participate in this study.

**Please initial one:**

\_\_\_\_\_ **YES**, I agree to participate in the optional longitudinal Amyloid PET assessment

\_\_\_\_\_ **NO**, I **do not** want to participate in the optional longitudinal Amyloid PET assessment. I am still allowed to take part in the study.

**OPTIONAL Tau PET ASSESSMENT**

If you do not want to participate in the optional Tau PET assessment, you will still be able to participate in this study. **Please initial one box:**

\_\_\_\_\_ **YES**, I agree to participate in the optional Tau PET assessment

\_\_\_\_\_ **NO**, I **do not** want to participate in the optional Tau PET assessment. I am still allowed to take part in the study.

**Participant**

Please confirm the name of your legal representative as follows;

---

<b>Legal Representative Name</b>	<b>Relationship to Participant</b>
Printed Name (CAPITALS)	

---

<b>Study Participant</b>		
Printed Name (CAPITALS)	Signature	Date

---

**CONSENT FORM Contd.**

**Study Title:** A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer's disease

**Principal Investigator** \_\_\_\_\_ **Dr. Emer MacSweeney**

**Participant Number** \_\_\_\_\_ **22-0413-** \_\_\_\_\_ **Participant Initials** \_\_\_\_\_

---

***Witness (if applicable)***

*Printed Name (CAPITALS)*

*Signature*

*Date*

- I have presented the study and answered the participant's questions.
- I will give the participant a copy of this signed and dated Informed Consent Form.

---

**Presenter (Investigator/Delegate)**

*Printed Name (CAPITALS)*

*Signature*

*Date*

**When completed: 1 for participant; 1 for researcher site file; 1 to be kept in medical notes**